コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ples were selected from the Penn FTD Center (University of Pennsylvania).
2 enerative Disease Research Brain Bank at the University of Pennsylvania.
3 genetics at the Perelman School of Medicine, University of Pennsylvania.
4 s relevance to recent human evolution at the University of Pennsylvania.
5 scans were performed at the Hospital of the University of Pennsylvania.
6 ted schools or hospitals affiliated with the University of Pennsylvania.
7 prehensive cancer center affiliated with the University of Pennsylvania.
8 MA), we analyzed 449 patients treated at the University of Pennsylvania.
9 s career as a Professor of Psychology at the University of Pennsylvania.
10 ital of Philadelphia and the Hospital of the University of Pennsylvania.
11 gen receptor T-cell therapy developed at the University of Pennsylvania.
12 or antibodies to DNER at the hospital of the University of Pennsylvania.
13 Diseases and Center for AIDS Research of the University of Pennsylvania.
14 thologists blinded to the prior diagnoses at University of Pennsylvania.
15 d Davis Institute of Health Economics at the University of Pennsylvania.
16 ess Unrestricted Grant; Parker Family Chair; University of Pennsylvania.
17 human samples from the ITMAT Biobank at the University of Pennsylvania.
20 ar disease (CVD) in women by following 1,564 University of Pennsylvania alumnae (mean age, 45.5 years
21 t study was conducted at the Hospital of the University of Pennsylvania among 2038 consecutive patien
22 , and April 31, 2013, at the Hospital of the University of Pennsylvania, an academic medical center.
23 anuary 7, 2015, and February 2, 2018, at the University of Pennsylvania and 51 148 DM/DBT examination
24 postpartum individuals who delivered at the University of Pennsylvania and had a hypertensive disord
25 viduals seen over a 5-year period within the University of Pennsylvania and the Mass General Brigham
26 noma were collected from the Hospital of the University of Pennsylvania and the radiologic archives o
28 logists' diagnoses from two research centres-University of Pennsylvania and University of Kentucky.
29 SOTRs with an EB BSI at the Hospital of the University of Pennsylvania and University of Maryland Me
30 on: 4.4% (Baylor), 8.0% (Georgetown), 32.6% (University of Pennsylvania), and 45.0% (Mount Sinai).
31 st Chair of the Department of Surgery at the University of Pennsylvania, and Dorsey's uncle), the new
33 l Center; Perelman School of Medicine at the University of Pennsylvania; and European Atherosclerosis
34 n college athletes at Harvard University and University of Pennsylvania, as well as the follow-up of
35 irst-time AF ablation at the Hospital of the University of Pennsylvania between 2018 and 2022 were id
37 consecutive adult alloHCT recipients at the University of Pennsylvania between April 2015 and Novemb
38 ents who received a diagnosis of MpBC at the University of Pennsylvania between January 2010 and May
39 utive series of WOP and IIT performed at the University of Pennsylvania between September 2001 and Fe
40 orted by the Cardiovascular Institute of the University of Pennsylvania, by the MedStar Health Resear
42 titute of Allergies and Infectious Diseases; University of Pennsylvania Center for AIDS Research.
43 st to the institutional review boards at the University of Pennsylvania, Children's Hospital of Phila
45 ber Sequencing test, and 6 measures from the University of Pennsylvania Computerized Neurocognitive B
48 ouble-blind clinical trial, conducted at the University of Pennsylvania Division of Plastic Surgery c
49 at 4 medical centers: Mass General Brigham, University of Pennsylvania, Emory University, and Fenway
50 apy for recurrent or metastatic HNSCC at the University of Pennsylvania from January 1, 2015, through
51 ts who underwent ERCP at the Hospital of the University of Pennsylvania, from 2009 and 2015, includin
54 ed from July 2017 through August 2018 at the University of Pennsylvania Health System (UPHS), an urba
55 es study was conducted among patients at the University of Pennsylvania Health System and in partners
57 ient and outpatient notes written within the University of Pennsylvania Health System from January 1,
59 January 1, 2005 to June 1, 2013, within the University of Pennsylvania Health System were identified
60 ine BioBank (PMBB) enrolling patients of the University of Pennsylvania Health System's clinical prac
61 ents at a large academic health care system (University of Pennsylvania Health System) and a private
62 through December 31, 2016, performed at the University of Pennsylvania Health System, a tertiary ref
63 inistered by the Center for Bioethics at the University of Pennsylvania Health System, extensively re
64 rom October 4, 2018, to May 27, 2021, at the University of Pennsylvania Health System, Philadelphia.
68 d fifty-one probands ascertained through the University of Pennsylvania high-risk clinic, all with co
69 in 2 tertiary care academic cancer centers (University of Pennsylvania Hospital Abramson Cancer Cent
70 med for 80 patients from the Hospital of the University of Pennsylvania (HUP) listed from July 1986 t
72 ents were recruited from the hospital of the University of Pennsylvania in Philadelphia, PA, USA.
73 onducted across wards of the Hospital of the University of Pennsylvania) included all persons eligibl
74 lected on 302 transplant recipients from the University of Pennsylvania, including 53 patients with e
75 udy included data from 2009 to 2020 from the University of Pennsylvania Integrated Neurodegenerative
76 eld professorships at McGill University, the University of Pennsylvania, Johns Hopkins University, an
77 37915, DK097307, HL115354, HL101779, and the University of Pennsylvania McCabe Fund Fellowship Award.
79 American; 41% female) were selected from the University of Pennsylvania Medicine BioBank with plasma
84 Predictors of outcome were determined at the Universities of Pennsylvania (PA, USA) and Barcelona (Sp
85 2 cohorts: (1) consecutive admissions at the University of Pennsylvania (Penn) with a primary dischar
86 at the Children's Hospital of Philadelphia, University of Pennsylvania (Penn), and via a Penn Dermat
89 nia, Berkeley), Donald Ringe and Ann Taylor (University of Pennsylvania, Philadelphia), and me, for a
90 ion therapy (n = 218) at the Hospital of the University of Pennsylvania, Philadelphia, or RT (n = 766
91 Mesothelioma Conference that was held at the University of Pennsylvania, Philadelphia, PA, May 13-16,
92 : New York Brain Bank, New York, USA (NYBB); University of Pennsylvania, Philadelphia, PA, USA (UPENN
93 erous German-speaking scholars coming to the University of Pennsylvania, Philadelphia, with Albert Kl
95 STIM1 promoter using the TESS search system (University of Pennsylvania) revealed four putative respo
96 aged 18 to 73 years and were enrolled in the University of Pennsylvania's Cutaneous Lupus Erythematos
97 8 to 2001; n = 26,291) and those seen by the University of Pennsylvania's Pigmented Lesion Group (PLG
100 school faculty with disabilities, drawing on University of Pennsylvania School of Medicine initiative
101 tion Education and Prevention Program at the University of Pennsylvania School of Medicine is a succe
102 s Hopkins University School of Medicine, the University of Pennsylvania School of Medicine, the Unive
104 sity of Pennsylvania Global Engagement Fund, University of Pennsylvania School of Nursing's Center fo
105 Coding (g = -0.67; 95% CI, -0.95 to -0.39), University of Pennsylvania Smell Identification Test (g
106 age- and sex-standardized performance on the University of Pennsylvania Smell Identification Test (UP
107 s old with current olfactory loss defined as University of Pennsylvania Smell Identification Test (UP
108 Participants were invited to complete a University of Pennsylvania Smell Identification Test (UP
109 on-Severity (CGI-S) smell questionnaire, the University of Pennsylvania Smell Identification Test (UP
110 ary outcome measures included changes in the University of Pennsylvania Smell Identification Test (UP
111 less Empirical Taste Test (WETT) and 40-item University of Pennsylvania Smell Identification Test (UP
112 SARS), Montreal Cognitive assessment (MoCA), University of Pennsylvania Smell Identification Test (UP
113 >/=8.90), sense of smell assessed using the University of Pennsylvania Smell Identification Test (UP
114 Participants were evaluated with the 40-item University of Pennsylvania Smell Identification Test (UP
117 Baseline olfaction was measured using the University of Pennsylvania Smell Identification Test (UP
118 isual analog scale [VAS] and psychophysical, University of Pennsylvania Smell Identification Test [UP
119 tilt positions using two different measures: University of Pennsylvania Smell Identification Test and
121 10-item scale performed comparably with the University of Pennsylvania Smell Identification Test in
123 score, Sinonasal Outcome Test 22 score, and University of Pennsylvania Smell Identification Test sco
124 nts and 100 lowest-risk participants, median University of Pennsylvania Smell Identification Test sco
127 Sino-Nasal Outcome Test-22 (SNOT-22) score, University of Pennsylvania Smell Identification Test, se
128 , and at 2 years, significant differences in University of Pennsylvania Smell Identification Test, Un
129 le factors), a keyboard-tapping task and the University of Pennsylvania Smell Identification Test.
130 ification was also assessed using a modified University of Pennsylvania Smell Identification Test.
131 on tomography and olfactory testing with the University of Pennsylvania Smell Identification Test.
132 40 normal subjects was compared by using the University of Pennsylvania Smell Identification Test.
133 y controls, in four olfactory tasks: (i) the University of Pennsylvania smell identification test; (i
136 w of students tested for tuberculosis at the University of Pennsylvania Student Health Service betwee
138 to a previous brain scanner developed at the University of Pennsylvania, the HEAD Penn-PET, but the d
139 blinded crossover trial was conducted at the University of Pennsylvania, the Philadelphia Veterans Af
140 nally followed Discovery Cohort based at the University of Pennsylvania (UPenn), we measured levels o
142 ortium and the Abramson Cancer Center of the University of Pennsylvania was convened on December 1, 2
143 red by The National Cancer Institute and the University of Pennsylvania, was held from December 1 to
146 ts seen in the Dermatology Department of the University of Pennsylvania, who were diagnosed with nonm
147 er patients treated from 1977 to 1995 at the University of Pennsylvania with conventional tangential
148 lant recipients between 2002 and 2006 at the University of Pennsylvania with follow-up through 2010.